Canada has world-class biotech science. Too often, the companies built on it grow up somewhere else. Clarissa Desjardins, co-founder and CEO of Montreal’s Congruence Therapeutics, joins John Stackhouse on the state of biotech and what Canada must do to keep more of what it builds. 

In this episode: 
• How AI is changing the way new drugs are discovered 
• Why China’s rise is reshaping the global industry 
• Why biotech stays invisible in Canada, even to investors 
• What it would take to grow Canadian companies to global scale at home 

 

Chapters:
0:00 Will Canada's medicines come from China? 
0:28 Biotech's missing place in Canada's agenda 
1:32 From scientist to entrepreneur 
3:47 Great science, too little commercialization 
6:03 How AI is changing drug discovery 
9:54 Why biotech is invisible, and underfunded 
13:15 Health sovereignty and the anchor-company gap 
18:33 China's rise in drug discovery 
21:31 What Canada needs to do next 
24:17 Closing thoughts 

CONNECT & SUBSCRIBE:

• Follow RBC Thought Leadership onLinkedIn
• Follow John Stackhouse onLinkedIn
• For more insights visit RBC Thought Leadership


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör RBC Thought Leadership, John Stackhouse. Innehållet i podden är skapat av RBC Thought Leadership, John Stackhouse och inte av, eller tillsammans med, Poddtoppen.